TrialBMC medicine2024

Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial.

Yanfei Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.